Modified Eligibility Criteria: Patient Access and Subpopulation Applicability vs Efficiency in Drug Development.
作者信息
O'Dwyer Peter J
机构信息
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Philadelphia, PA, USA.
出版信息
J Natl Cancer Inst. 2022 Nov 14;114(11):1429-1430. doi: 10.1093/jnci/djac155.
Abstract
摘要
相似文献
1
Modified Eligibility Criteria: Patient Access and Subpopulation Applicability vs Efficiency in Drug Development.修改后的资格标准：药物研发中的患者可及性、亚组适用性与效率
J Natl Cancer Inst. 2022 Nov 14;114(11):1429-1430. doi: 10.1093/jnci/djac155.
2
Semantic query generation from eligibility criteria in clinical trials.从临床试验的纳入标准生成语义查询。
AMIA Annu Symp Proc. 2007 Oct 11:1070.
3
Improving Diversity in Clinical Trials by Using Real-world Data to Define Eligibility Criteria.利用真实世界数据定义纳入标准以提高临床试验的多样性
JAMA Oncol. 2023 Apr 1;9(4):455-456. doi: 10.1001/jamaoncol.2022.7170.
4
WHO medical eligibility criteria update.世界卫生组织医学适用性标准更新。
Contraception. 2016 Sep;94(3):193-4. doi: 10.1016/j.contraception.2016.07.001.
5
Desiderata for Major Eligibility Criteria in Breast Cancer Clinical Trials.乳腺癌临床试验主要入选标准的必备条件
AMIA Annu Symp Proc. 2015 Nov 5;2015:2025-34. eCollection 2015.
6
Conformity between protocol eligibility criteria for electronic patient identification: a comparison of clinical trials.电子患者识别的方案入选标准之间的一致性：临床试验比较
Stud Health Technol Inform. 2013;192:1167.
7
Feasibility platform for stroke studies: an online tool to improve eligibility criteria for clinical trials.中风研究的可行性平台：一种用于改善临床试验入选标准的在线工具。
Stroke. 2015 Jan;46(1):137-42. doi: 10.1161/STROKEAHA.114.007124. Epub 2014 Nov 13.
8
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group.通过减少限制性排除标准的使用来扩大肺癌临床试验的参与机会：多利益相关方工作组的观点。
Clin Lung Cancer. 2020 Jul;21(4):295-307. doi: 10.1016/j.cllc.2020.02.008. Epub 2020 Feb 26.
9
Clinical Trial Eligibility Criteria: A Structural Barrier to Diversity in Clinical Trial Enrollment.临床试验资格标准：临床试验入组中多样性的结构性障碍。
J Clin Oncol. 2022 Jul 10;40(20):2183-2185. doi: 10.1200/JCO.22.00537. Epub 2022 Apr 15.
10
Extraction and Prevalence of Structured Data Elements in Free-Text Clinical Trial Eligibility Criteria.自由文本临床试验纳入标准中结构化数据元素的提取与患病率
Stud Health Technol Inform. 2019;258:226-230.
本文引用的文献
1
Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials.实施美国国家癌症研究所临床试验的现代化资格标准。
J Natl Cancer Inst. 2022 Nov 14;114(11):1437-1440. doi: 10.1093/jnci/djac152.
2
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement.持续拓宽资格标准以使临床试验更具代表性和包容性：美国临床肿瘤学会 - 癌症研究之友联合研究声明
Clin Cancer Res. 2021 May 1;27(9):2394-2399. doi: 10.1158/1078-0432.CCR-20-3852. Epub 2021 Feb 9.
3
Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation.系统评价和荟萃分析癌症临床试验参与的结构、临床以及医生和患者障碍的程度。
J Natl Cancer Inst. 2019 Mar 1;111(3):245-255. doi: 10.1093/jnci/djy221.
4
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.扩大入选标准以使临床试验更具代表性：美国临床肿瘤学会与癌症研究之友联合研究声明
J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.
5
Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials.重新评估资格标准——平衡患者保护与参与肿瘤学试验
N Engl J Med. 2017 Apr 20;376(16):1504-1505. doi: 10.1056/NEJMp1615879.
6
Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials.晚期非小细胞肺癌患者参与III期化疗试验的资格。
BMC Cancer. 2009 Apr 29;9:130. doi: 10.1186/1471-2407-9-130.
7
Including persons with HIV infection in cancer clinical trials.将感染艾滋病毒的人纳入癌症临床试验。
J Clin Oncol. 2008 Mar 1;26(7):1027-32. doi: 10.1200/JCO.2007.14.5532.
8
Public attitudes toward participation in cancer clinical trials.公众对参与癌症临床试验的态度。
J Clin Oncol. 2003 Mar 1;21(5):830-5. doi: 10.1200/JCO.2003.02.105.
9
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.四种化疗方案用于晚期非小细胞肺癌的比较。
N Engl J Med. 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954.
10
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .东部肿瘤协作组（ECOG）E1594研究中体能状态为2的患者的结局：一项针对转移性非小细胞肺癌患者的II期试验
Cancer. 2001 Nov 15;92(10):2639-47. doi: 10.1002/1097-0142(20011115)92:10<2639::aid-cncr1617>3.0.co;2-8.
Zotero 插件